ESMO-Magnitude of Clinical Benefit Scale

The ESMO-MCBS is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies at the time of approval.

The below filter has been created to provide a centralised location of cancer medicines that have been scored using ESMO-MCBS v1.1 and published by ESMO.

ESMO-MCBS grading

Curative setting grading - A (best), B, C (worst):

  • Form 1   - For new approaches to adjuvant therapy or new potentially curative therapies

Non-curative setting grading - 5 (best), 4, 3, 2, 1 (worst):

  • Form 2a   - For therapies that are not likely to be curative with primary endpoint of OS 
  • Form 2b   - For therapies that are not likely to be curative with primary endpoint PFS 
  • Form 2c   - For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies 
  • Form 3     - For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR 

For full information please click here

The ESMO-MCBS Score Card

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. Detailed scorecards will be available to ESMO Members in December 2018.This content will be updated regularly and communicated to ESMO Members.

OR
OR
Tested Agent Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Score
Card
Trastuzumab Chemotherapy Adjuvant or neo-adjuvant HER2 positive tumours Breast Cancer Breast Cancer HER2+ Early
A
Piccart-Gebhart et al, N Engl J Med 2005; 353:1659-1672 Icon to see scorecard 1 1
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel (Randomised phase II study) Neo-adjuvant HER2 overexpressed invasive ductal breast Breast Cancer Breast Cancer HER2+ Early
C
Gianni et al, Lancet Oncol 2012; 13:25-32
Gianni et al, Lancet Oncol 2016; 17:791-800
Icon to see scorecard 2 1
T-DM1 Lapatinib + capecitabine 2nd line metastatic after trastuzumab failure (extensive crossover) Breast Cancer Breast Cancer HER2+ Metastatic
4
Verma et al, N Engl J Med 2012; 367: 1783-1791
Welslau et al, Cancer 2014; 120: 642-651
Icon to see scorecard 3 1
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo 1st line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Swain et al, N Engl J Med 2015; 372:724-734
Baselga et al, N Engl J Med 2012; 366:109-119
Cortes et al, Ann Oncol 2013; 24:2630-2635
Icon to see scorecard 4 1
Trastuzumab Lapatinib Lapatinib 3rd line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Blackwell et al, J Clin Oncol 2012; 30:2585-2592 Icon to see scorecard 5 1
Palbociclib Fulvestrant Fulvestrant + placebo 2nd line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
4
Cristofanilli et al, Lancet Oncol 2016; 17:425-439 Icon to see scorecard 6 1
Palbociclib Letrozole Letrozole + placebo 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Finn et al, N Engl J Med 2016; 375:1925-1936 Icon to see scorecard 7 1
Palbociclib Letrozole Letrozole (Randomised phase II study) 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Finn et al, Lancet Oncol 2015; 16:25-35 Icon to see scorecard 8 1
Ribociclib Letrozole Letrozole + placebo 1st line metastatic post-menopause HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Hortobagyi et al, Ann Oncol 2018; 29:1541-1547 Icon to see scorecard 9 1
Lapatinib Capecitabine Capecitabine 2nd line metastatic after trastuzumab failure Breast Cancer Breast Cancer HER2+ Metastatic
3
Geyer et al, N Engl J Med 2006; 355:2733-2743 Icon to see scorecard 10 1